U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H22FNO.ClH
Molecular Weight 299.811
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MELPERONE HYDROCHLORIDE

SMILES

Cl.CC1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1

InChI

InChIKey=MQHYXXIJLKFQGY-UHFFFAOYSA-N
InChI=1S/C16H22FNO.ClH/c1-13-8-11-18(12-9-13)10-2-3-16(19)14-4-6-15(17)7-5-14;/h4-7,13H,2-3,8-12H2,1H3;1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C16H22FNO
Molecular Weight 263.3504
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Melperone is an antipsychotic drug which is used in Europe for the treatment of sleep disorders, agitation and confusion states. The exact mechanism of melperone action is unknown.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MELPERON

Approved Use

Melperon is used to treat sleep disorders, confusion states, and to suppress psychomotor restlessness and excitement, especially in geriatric and psychiatric patients.
Primary
MELPERON

Approved Use

Melperon is used to treat sleep disorders, confusion states, and to suppress psychomotor restlessness and excitement, especially in geriatric and psychiatric patients.
Primary
MELPERON

Approved Use

Melperon is used to treat sleep disorders, confusion states, and to suppress psychomotor restlessness and excitement, especially in geriatric and psychiatric patients.
PubMed

PubMed

TitleDatePubMed
Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor.
2001 Oct
Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism.
2002 Nov 29
Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine.
2003 Jan
The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia.
2003 Jan 1
A comparison of two doses of melperone, an atypical antipsychotic drug, in the treatment of schizophrenia.
2003 Jul 1
Screening, library-assisted identification and validated quantification of fifteen neuroleptics and three of their metabolites in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization.
2003 Mar
P-glycoprotein is a factor in the uptake of dextromethorphan, but not of melperone, into the mouse brain: evidence for an overlap in substrate specificity between P-gp and CYP2D6.
2004 Dec
[The case of a 86-years old woman first diagnosed with Huntington's disease].
2004 Nov
Atypical and typical antipsychotic drug interactions with the dopamine D2 receptor.
2005 Feb
Antipsychotic drugs and QT prolongation.
2005 Sep
Cytochrome P450 2D6 dependent metabolization of risperidone is inhibited by melperone.
2006 Apr
The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).
2008 Dec 22
Antipsychotics and risk of venous thromboembolism: A population-based case-control study.
2009 Aug 9
Acute administration of clozapine and risperidone altered dopamine metabolism more in rat caudate than in nucleus accumbens: a dose-response relationship.
2010 Apr-Jun
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010 Dec
Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist.
2010 Feb
Four-digit replantation in a mentally retarded person: a case report.
2010 Sep 30
Patents

Sample Use Guides

The recommended dose of melperone (in form of hydrochloride salt) is 25-75 mg/day. In the case of restless and confused patients the drug is given at a dose of 50-100 mg at the beginning of the treatment. The dose can be increased up to 200 mg if necessary. In severe disorders of confusion and confusion with aggression and hallucinatory conditions, the daily dose can be increased to up to 400 mg melperone HCl.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:25:35 UTC 2023
Edited
by admin
on Fri Dec 15 15:25:35 UTC 2023
Record UNII
88G640374K
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MELPERONE HYDROCHLORIDE
MART.   MI   WHO-DD  
Common Name English
MELPERONE HCL
Common Name English
METYLPERON HYDROCHLORIDE
Common Name English
1-(4-FLUOROPHENYL)-4-(4-METHYL-1-PIPERIDINYL)-1-BUTANONE HYDROCHLORIDE
Systematic Name English
NSC-760102
Code English
MELPERONE HYDROCHLORIDE [MI]
Common Name English
Melperone hydrochloride [WHO-DD]
Common Name English
MELPERONE HYDROCHLORIDE [MART.]
Common Name English
Code System Code Type Description
RXCUI
289623
Created by admin on Fri Dec 15 15:25:35 UTC 2023 , Edited by admin on Fri Dec 15 15:25:35 UTC 2023
PRIMARY RxNorm
MERCK INDEX
m7165
Created by admin on Fri Dec 15 15:25:35 UTC 2023 , Edited by admin on Fri Dec 15 15:25:35 UTC 2023
PRIMARY Merck Index
MESH
C008522
Created by admin on Fri Dec 15 15:25:35 UTC 2023 , Edited by admin on Fri Dec 15 15:25:35 UTC 2023
PRIMARY
NSC
760102
Created by admin on Fri Dec 15 15:25:35 UTC 2023 , Edited by admin on Fri Dec 15 15:25:35 UTC 2023
PRIMARY
EVMPD
SUB14503MIG
Created by admin on Fri Dec 15 15:25:35 UTC 2023 , Edited by admin on Fri Dec 15 15:25:35 UTC 2023
PRIMARY
PUBCHEM
15386
Created by admin on Fri Dec 15 15:25:35 UTC 2023 , Edited by admin on Fri Dec 15 15:25:35 UTC 2023
PRIMARY
ECHA (EC/EINECS)
216-599-9
Created by admin on Fri Dec 15 15:25:35 UTC 2023 , Edited by admin on Fri Dec 15 15:25:35 UTC 2023
PRIMARY
FDA UNII
88G640374K
Created by admin on Fri Dec 15 15:25:35 UTC 2023 , Edited by admin on Fri Dec 15 15:25:35 UTC 2023
PRIMARY
EPA CompTox
DTXSID10936649
Created by admin on Fri Dec 15 15:25:35 UTC 2023 , Edited by admin on Fri Dec 15 15:25:35 UTC 2023
PRIMARY
CAS
1622-79-3
Created by admin on Fri Dec 15 15:25:35 UTC 2023 , Edited by admin on Fri Dec 15 15:25:35 UTC 2023
PRIMARY
SMS_ID
100000092068
Created by admin on Fri Dec 15 15:25:35 UTC 2023 , Edited by admin on Fri Dec 15 15:25:35 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY